CARLSBAD, Calif., Oct. 10, 2013 /PRNewswire/ -- Advanced Biologics, developers and marketers of OsteoAMP® Allogeneic Morphogenetic Protein, announced today that it will be presenting new data and also showcasing a new graft delivery device at two of the larger, global orthopaedic meetings this week; the North American Spine Society (NASS) annual meeting in New Orleans, LA, and the Combined Meeting of Orthopaedic Research Societies (CORS) meeting in Venice, Italy.
An abstract titled, 'Osteoinductivity and Osteogenicity of Leading Allograft Bone Products,' analyzed the bone forming potential of 2 leading allograft products (OsteoAMP® and the leading allogeneic-derived stem cell product, Osteocel® Plus). The study, utilizing three different lots of both OsteoAMP® and Osteocel® Plus, implanted product into muscle pouches of athymic rats (performed by an independent lab). Implants were assessed for bone formation using H&E histology and the subsequent histomorphometric analysis exhibited increasing osteonecrosis over time for the stem cell product, whereas, new bone formation and cellularity was shown to increase over all time points for OsteoAMP. The study has been submitted for additional peer review.
Further complementing the clinical aspects of OsteoAMP, a new graft delivery device has been introduced by the company this month. The new device utilizes a vented membrane and presents a more consistent and accurate level of hydration for the surgeons, facilitating better saturation and handling of the OsteoAMP products.
"This additional data further substantiates OsteoAMP as a viable option for surgeons, hospitals and patients who are not satisfied with their results using stem cells or rhBMP-2," stated President, Amit Govil. "With the addition of our new delivery device, early feedback from surgeons and OR staff has been extremely positive and we are excited for its full roll out."
About Advanced Biologics
Founded in 2009, Advanced Biologics (ABC) is a privately-held company focused on developing innovative and clinically relevant biologic solutions across a wide degree of medical specialties. The OsteoAMP® family of osteoinductive/conductive products is the first line of orthobiologic offerings produced by ABC. ABC has been recognized three times as 'Best New Technology' during the Orthopedics This Week Spine Technology Awards. www.advancedbiologics.com
SOURCE Advanced Biologics